Dodecyl creatine ester and lipid nanocapsule: a double strategy for the treatment of creatine transporter deficiency

Creatine transporter (CT) deficiency is characterized by mutations in the gene encoding CT, leading to impaired transport of creatine at the cell membrane. Patients with this disease would thus benefit from replenishment of creatine inside the brain cells. We report a therapeutic strategy based on t...

Full description

Saved in:
Bibliographic Details
Published in:Nanomedicine (London, England) England), 2015-01, Vol.10 (2), p.185-191
Main Authors: Trotier-Faurion, Alexandra, Passirani, Catherine, Béjaud, Jérôme, Dézard, Sophie, Valayannopoulos, Vassili, Taran, Fréderic, de Lonlay, Pascale, Benoit, Jean-Pierre, Mabondzo, Aloïse
Format: Article
Language:English
Subjects:
blood-brain barrier
Blood-Brain Barrier - metabolism
Brain Diseases, Metabolic, Inborn - metabolism
creatine
Creatine - deficiency
Creatine - metabolism
creatine transporter deficiency
dodecyl creatine ester
Fibroblasts - metabolism
Humans
Life Sciences
lipid nanocapsule
Lipids - chemistry
Mental Retardation, X-Linked - metabolism
Nanocapsules - chemistry
Plasma Membrane Neurotransmitter Transport Proteins - deficiency
Plasma Membrane Neurotransmitter Transport Proteins - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Creatine transporter (CT) deficiency is characterized by mutations in the gene encoding CT, leading to impaired transport of creatine at the cell membrane. Patients with this disease would thus benefit from replenishment of creatine inside the brain cells. We report a therapeutic strategy based on the use of dodecyl creatine ester incorporated into lipid nanocapsules (LNCs). The dodecyl creatine ester was incorporated in the shells of LNCs using Transcutol (Gattefossé SAS, Saint-Priest, France). The interactions of dodecyl creatine ester encapsulated in LNCs with an cell-based blood-brain barrier model was studied. The entry of the dodecyl creatine ester encapsulated in LNCs and the conversion of dodecyl creatine ester to creatine in the cells were also studied in the pathological context of CT deficiency. We showed that these LNCs can cross the blood-brain barrier and enter brain endothelial cells. In human fibroblasts lacking functional CT, all or part of the dodecyl creatine ester was released from the LNCs and biotransformed to creatine, thus indicating the value of this strategy in this therapeutic context. Original submitted 2 April 2013; Revised submitted 28 October 2013
ISSN:1743-5889
1748-6963
1748-6963
DOI:10.2217/nnm.13.205